EXACT Therapeutics AS Announces Allowance of Patent Application in Europe for Acoustic Cluster Therapy (ACT®)
OSLO/LONDON, 22 December 2021: Christmas came early at EXACT Therapeutics AS (“EXACT-Tx”, or “the Company”, Euronext Growth: EXTX) as the clinical-stage precision health company developing the proprietary ultrasound-mediated drug delivery platform Acoustic Cluster Therapy (ACT®) for use across multiple diseases, announces today that allowability has been found for its patent application in Europe (publication no. EP3049117) for its innovative Acoustic Cluster Therapy® technology.
The allowed patent claims cover EXACT-Tx’s unique microbubble/ microdroplet formulation (PS101) and its use, co-administered with a range of pharmaceutical agents for ultrasound mediated drug targeting. This is an important step in securing EXACT-Tx’s mission to enhance the therapeutic outcome of the standard of care across drug classes for the benefit of patients across diseases.
Dr Masha Strømme, Executive Chair of the Board, commented: “We are delighted with the decision of the European Patent Office in allowing this important patent for ACT®, which complements the existing grant in China in November 2019 and in Japan in April 2021. This core patent family represents the foundation of our dynamic IP strategy, which encompasses the use of ACT® with a variety of therapeutics across a multitude of indications”.
ENDS
For more information, please contact:
Dominic Moreland
EXACT Therapeutics
Email: dominic@exact-tx.com
Optimum Strategic Communications
Hollie Vile/ Manel Mateus/ Vici Rabbetts
Tel: +44 (0) 208 078 4357
Email: Exact@optimumcomms.com
About EXACT Therapeutics AS
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and brain diseases. www.exact-tx.com
About ACT®
•ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent.
•ACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration.
•Initial focus of the Company is in oncology, however the ACT® platform has potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and product classes.
Forward looking statements
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by this forward-looking statement.